Efficacy of zofenopril in combination with thiazide diuretics in patients with acute myocardial infarction: a pooled individual data analysis of four randomized, double-blind, controlled, prospective studies

References

• PiepoliMFHoesAWAgewallS2016 European Guidelines on cardiovascular disease prevention in clinical practice: the Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR)Atherosclerosis201625220727427664503
   PubMed Web of Science ®Google Scholar
• AronowWSOffice management after myocardial infarctionAm J Med2010123759359520609678
   PubMed Web of Science ®Google Scholar
• WaeberBCombination therapy with ACE inhibitors/angiotensin II receptor antagonists and diuretics in hypertensionExpert Rev Cardiovasc Ther200311435015030296
   PubMedGoogle Scholar
• BaineyKRArmstrongPWFonarowGCUse of renin-angiotensin system blockers in acute coronary syndromes: findings from Get With the Guidelines-Coronary Artery Disease ProgramCirc Cardiovasc Qual Outcomes20147222723524569634
   PubMed Web of Science ®Google Scholar
• AmsterdamEAWengerNKBrindisRGACC/AHA Task Force Members; Society for Cardiovascular Angiography and Interventions and the Society of Thoracic Surgeons2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Practice GuidelinesCirculation2014130252354239425249586
   PubMed Web of Science ®Google Scholar
• AmbrosioniEBorghiCMagnaniBThe effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The Survival of Myocardial Infarction Long-Term Evaluation (SMILE) Study InvestigatorsN Engl J Med1995332280857990904
   PubMed Web of Science ®Google Scholar
• BorghiCAmbrosioniESurvival of Myocardial Infarction Long-Term Evaluation-2 Working PartyDouble-blind comparison between zofenopril and lisinopril in patients with acute myocardial infarction: results of the Survival of Myocardial Infarction Long-Term Evaluation-2 (SMILE-2) StudyAm Heart J20031451808712514658
   PubMed Web of Science ®Google Scholar
• BorghiCAmbrosioniESurvival of Myocardial Long-term Evaluation Study GroupEffects of zofenopril on myocardial ischemia in post-myocardial infarction patients with preserved left ventricular function: the Survival of Myocardial Infarction Long-term Evaluation (SMILE)-ISCHEMIA StudyAm Heart J20071533445.e7e14
   Web of Science ®Google Scholar
• BorghiCAmbrosioniENovoSVinereanuDAmbrosioGSMILE-4 Working PartyComparison between zofenopril and ramipril in combination with acetylsalicylic acid in patients with left ventricular systolic dysfunction after acute myocardial infarction: results of a randomized, double-blind, parallel-group, multicenter, European study (SMILE-4)Clin Cardiol201235741642322707187
   PubMed Web of Science ®Google Scholar
• OmboniSMalaccoEParatiGZofenopril plus hydrochlorothiazide fixed combination in the treatment of hypertension and associated clinical conditionsCardiovasc Ther200927427528819832845
   PubMed Web of Science ®Google Scholar
• BorghiCOmboniSZofenopril plus hydrochlorothiazide combination in the treatment of hypertension: an updateExpert Rev Cardiovasc Ther20141291055106525098297
   PubMedGoogle Scholar
• Agabiti-RoseiEManolisAZavaDOmboniSZODIAC Study GroupZofenopril plus hydrochlorothiazide and irbesartan plus hydrochlorothiazide in previously treated and uncontrolled diabetic and non-diabetic essential hypertensive patientsAdv Ther201431221723324415271
   PubMed Web of Science ®Google Scholar
• MalaccoEOmboniSAntihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination for treatment in metabolic syndromeAdv Ther20072451006101518029326
   PubMed Web of Science ®Google Scholar
• AlbertiKGEckelRHGrundySMInternational Diabetes Federation Task Force on Epidemiology and PreventionNational Heart, Lung, and Blood InstituteAmerican Heart AssociationWorld Heart FederationInternational Atherosclerosis SocietyInternational Association for the Study of ObesityHarmonizing the metabolic syndrome: a joint interim statement of the International Diabetes Federation Task Force on Epidemiology and Prevention; National Heart, Lung, and Blood Institute; American Heart Association; World Heart Federation; International Atherosclerosis Society; and International Association for the Study of ObesityCirculation200912061640164519805654
   PubMed Web of Science ®Google Scholar
• RiordanJFAngiotensin-I-converting enzyme and its relativesGenome Biol20034822512914653
   PubMed Web of Science ®Google Scholar
• DesideriGGrassiDCroceGDifferent effects of angiotensin converting enzyme inhibitors on endothelin-1 and nitric oxide balance in human vascular endothelial cells: evidence of an oxidant-sensitive pathwayMediators Inflamm2008200830508719079593
   PubMed Web of Science ®Google Scholar
• LiuXEngelmanRMRousouJACordisGADasDKAttenuation of myocardial reperfusion injury by sulfhydryl-containing angiotensin converting enzyme inhibitorsCardiovasc Drugs Ther1992644374431387799
   PubMed Web of Science ®Google Scholar
• MakITFreedmanAMDickensBFWeglickiWBProtective effects of sulfhydryl-containing angiotensin converting enzyme inhibitors against free radical injury in endothelial cellsBiochem Pharmacol1990409216921752173602
   PubMed Web of Science ®Google Scholar
• García-EstañJOrtizMCO’ValleFEffects of angiotensin-converting-enzyme inhibitors in combination with diuretics on blood pressure and renal injury in nitric oxide-deficiency-induced hypertension in ratsClin Sci (Lond)2006110222723316197366
   PubMed Web of Science ®Google Scholar
• NapoliCSicaVde NigrisFSulfhydryl angiotensin-converting enzyme inhibition induces sustained reduction of systemic oxidative stress and improves the nitric oxide pathway in patients with essential hypertensionAm Heart J20041481e515215814
   PubMed Web of Science ®Google Scholar
• NapoliCBruzzeseGIgnarroLJLong-term treatment with sulfhydryl angiotensin-converting enzyme inhibition reduces carotid intima-media thickening and improves the nitric oxide/oxidative stress pathways in newly diagnosed patients with mild to moderate primary hypertensionAm Heart J200815661154.e1e819033012
   PubMed Web of Science ®Google Scholar
• EvangelistaSManziniSAntioxidant and cardioprotective properties of the sulphydryl angiotensin-converting enzyme inhibitor zofenoprilJ Int Med Res2005331425415651714
   PubMed Web of Science ®Google Scholar
• WestendorpBSchoemakerRGvan GilstWHvan VeldhuisenDJBuikemaHHydrochlorothiazide increases plasma or tissue angiotensin-converting enzyme-inhibitor drug levels in rats with myocardial infarction: differential effects on lisinopril and zofenoprilEur J Pharmacol20055271–314114916310764
   PubMed Web of Science ®Google Scholar
• MalaccoEOmboniSStudy GroupAntihypertensive effect of zofeno-pril plus hydrochlorothiazide versus zofenopril monotherapy in patients with essential hypertension according to their cardiovascular risk level: a post hoc analysisCurr Ther Res Clin Exp200869323224224692801
   PubMed Web of Science ®Google Scholar
• ModestiPAOmboniSTaddeiSZofenopril or irbesartan plus hydrochlorothiazide in elderly patients with isolated systolic hypertension untreated or uncontrolled by previous treatment: a double-blind, randomized studyJ Hypertens201634357658726703917
   PubMed Web of Science ®Google Scholar